Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FOXM1 contributes to treatment failure in acute myeloid leukemia.

JCI insight - 9 Aug 2018

Khan Irum, Halasi Marianna, Patel Anand, Schultz Rachael, Kalakota Nandini, Chen Yi-Hua, Aardsma Nathan, Liu Li, Crispino John D, Mahmud Nadim, Frankfurt Olga, Gartel Andrei L

Abstract excerpt

Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. Our previous work has shown that these favorable outcomes are linked to the cytoplasmic relocalization and inactivation of FOXM1 driven by mutated NPM1. Here, we went on to confirm the important role of FOXM1 in increased chemoresistance in AML. A multiinstitution retrospective study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Boron Compounds
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Nucleophosmin

Share to Primary Cell Culture

Share to Proteasome Inhibitors

Share to Treatment Failure

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30089730
DOI: 10.1172/jci.insight.121583
PMCID: PMC6129129

Genes

FOXM1
NPM1
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOXM1 contributes to treatment failure in acute myeloid leukemia.PMID 30089730Read ↗

Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancerSemantic proximity Read ↗

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice.Semantic proximity Read ↗

Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid LeukemiaSemantic proximity Read ↗

NPM1 Biology in Myeloid Neoplasia.Semantic proximity Read ↗

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.Semantic proximity Read ↗

Mutant NPM1 Maintains the Leukemic State through HOX Expression.Semantic proximity Read ↗

Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatmentsSemantic proximity Read ↗

Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemiaSemantic proximity Read ↗

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.Semantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in <i>NPM1</i> -mutated AMLSemantic proximity Read ↗

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cellsSemantic proximity Read ↗

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.